GlassScriptPhysician profile
David Bjelica
NPI 1336281369
$1,480.88
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,208 · 2020: $203 · 2021: $55.94 · 2022: $13.33.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $346.82 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $292.59 | 2019-2020 | |
| Dexcom, INC. | $215.45 | 2019 | |
| Lilly USA, LLC | $166.68 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $122.78 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $114.62 | 2019 | |
| Amarin Pharma, INC. | $68.30 | 2019-2020 | |
| Novo Nordisk INC | $58.01 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $33.99 | 2019 | |
| Medtronic Minimed, INC. | $28.86 | 2019 | |
| Companion Medical, INC. | $21.01 | 2019 | |
| Abbott Laboratories | $11.77 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Bjelica listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.